

Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information request regarding the use of Biologic medicines. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 1 Patient
- Adalimumab Biosimilar 26 Patients
- Apremilast – Unable to answer this question due to various clinics using the same Cost Centre
- Bimekizumab No Patients
- Brodalumab 9 Patients
- Certolizumab 1 Patient
- Dimethyl fumarate – Unable to answer this question due to various clinics using the same Cost Centre
- Etanercept – Enbrel 1 Patient
- Etanercept Biosimilar No Patients
- Guselkumab 27 Patients
- Infliximab - Remicade– Unable to answer this question due to various clinics using the same Cost Centre
- Infliximab Biosimilar– Unable to answer this question due to various clinics using the same Cost Centre
- Ixekizumab 4 Patients
- Risankizumab No Patients
- Secukinumab 63 Patients
- Tildrakizumab 4 Patients
- Ustekinumab 21 Patients

Q2. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 16 Patients
- Adalimumab Biosimilar 167 Patients
- Filgotinib No Patients
- Golimumab 4 Patients
- Infliximab – Remicade – Unable to answer this question due to various clinics using the same Cost Centre
- Infliximab Biosimilar – Unable to answer this question due to various clinics using the same Cost Centre
- Ozanimod No Patients
- Tofacitinib – Unable to answer this question due to various clinics using the same Cost Centre
- Ustekinumab 60 Patients

Our Ref: 182/2022

JANUARY 2022

- Vedolizumab– Unable to answer this question due to various clinics using the same Cost Centre